Ivonescimab Extends Overall Survival Over Pembrolizumab in PD-L1-Positive Advanced Lung Cancer
A prespecified interim analysis of the phase 3 HARMONi-2 trial shows ivonescimab achieved median overall survival of 30.8 months versus ...
Tag: PD-L1-positive advanced lung cancer
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!